BioPharma Resources

Drug Trial Radar · NCT07083154

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Effects of Mazdutide on Cognitive Function in Patients With Type 2 Diabetes and Early-Stage Cognitive Impairment: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Sep 27, 2025

Primary completion

Aug 1, 2029

Study completion Aug 1, 2029

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Nanjing First Hospital, Nanjing Medical University; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Xiangya Hospital of Central South University; Huadong Hospital; Jiangsu Province Hospital of Traditional Chinese Medicine; Changzhou No.2 People's Hospital; The Second Affiliated Hospital of Dalian Medical University
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and early-stage cognitive impairment, defined as mild cognitive impairment (MCI) or mild dementia. Participants are randomized 1:1 to receive once-weekly subcutaneous mazdutide, with dose escalation according to the protocol, or matching placebo, in addition to background glucose-lowering therapy. The primary objective is to determine whether 76 weeks of mazdutide treatment can slow cognitive and functional decline compared with placebo in this population.

Conditions

  • Dementia, Mild
  • Mild Cognitive Impairment
  • Type 2 Diabetes

Interventions

  • MazdutideDrug

    Mazdutide is administered once weekly by subcutaneous injection using a prefilled autoinjector pen, preferably on the same day each week. Treatment is initiated at 2.0 mg once weekly and up-titrated to 4.0 mg once weekly during Weeks 4-12 according to individual tolerability. After at least 4 weeks at 4.0 mg, further escalation to 6.0 mg once weekly may be considered if prespecified criteria are met. Participants who are unable to tolerate a given dose may continue treatment at the highest tolerated dose. The total treatment duration is 76 weeks.

  • PlaceboDrug

    Matching placebo is administered once weekly by subcutaneous injection using a prefilled autoinjector pen. Participants will undergo the same blinded titration and dose-adjustment schedule as the mazdutide group, including corresponding 2.0 mg, 4.0 mg, and, where applicable, 6.0 mg dosing levels. Participants unable to tolerate a given dosing level may remain at the highest tolerated level. The total treatment duration is 76 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Integrated Alzheimer's Disease Rating Scale (iADRS) Score ChangeTime frame: From Baseline to Week 76

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Endocrinology, Huadong Hospital Affiliated to Fudan University

    Shanghai, China · Recruiting

  • Department of Endocrinology, Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Department of Endocrinology, Changzhou No.2 People's Hospital

    Changzhou, Jiangsu, China · Recruiting

  • Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

    Nanjing, Jiangsu, China · Recruiting

  • Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Not yet recruiting

  • Department of Endocrinology, Shanghai General Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.